APA (7th ed.) Citation

Stahl, M., Roehmel, J., Eichinger, M., Doellinger, F., Naehrlich, L., Kopp, M. V., . . . Mall, M. A. (2023). Effects of lumacaftor/ivacaftor on cystic fibrosis disease progression in children 2 through 5 years of age homozygous for F508del-CFTR: A phase 2 placebo-controlled clinical trial. Annals of the American Thoracic Society, 20(8), . https://doi.org/10.1513/AnnalsATS.202208-684OC

Chicago Style (17th ed.) Citation

Stahl, Mirjam, et al. "Effects of Lumacaftor/ivacaftor on Cystic Fibrosis Disease Progression in Children 2 Through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial." Annals of the American Thoracic Society 20, no. 8 (2023). https://doi.org/10.1513/AnnalsATS.202208-684OC.

MLA (9th ed.) Citation

Stahl, Mirjam, et al. "Effects of Lumacaftor/ivacaftor on Cystic Fibrosis Disease Progression in Children 2 Through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial." Annals of the American Thoracic Society, vol. 20, no. 8, 2023, https://doi.org/10.1513/AnnalsATS.202208-684OC.